Aldosterone in congestive heart failure

New England Journal of Medicine

Volumn 345, Issue 23, 2001, Pages 1689-1697

  Weber, K T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE;

CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; DRUG EFFICACY; HUMAN; HYPERALDOSTERONISM; NONHUMAN; PATHOPHYSIOLOGY; POTASSIUM EXCRETION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION; VASCULAR ENDOTHELIUM; WATER RETENTION;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ALDOSTERONE; RENIN-ANGIOTENSIN SYSTEM; SODIUM;

EID: 0035818917     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra000050     Document Type: Review

References (86)

1. The physiology of congestive heart failure
2. The metabolism of aldosterone in normal subjects and in patients with hepatic cirrhosis
3. Observations on the sodium-retaining corticoid (aldosterone) in the urine of children and adults in relation to sodium balance and edema
4. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system
5. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
6. The effect of spironolactone on morbidity, and mortality in patients with severe heart failure
7. Evolution and the cardiac patient
8. Renal physiology
9. Evolution and the cardiac, patient
10. Comparative endocrinology of renin and angiotensin
11. 'Til death do us part: A case of failed affection
12. Postural augmentation of plasma renin activity and aldosterone excretion in normal people
13. Interrelationship of electrolytes, juxtaglomerular cells and hypertension
14. Adaptation to potassium
15. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis
16. Physiology of aldosterone
17. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion
18. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: A potential link between the renin-angiotensin system and thrombosis
19. Hormones and fibrosis: A case for lost reciprocal regulation
20. Angiotensin II and extracellular matrix homeostasis
21. Mechanisms of protective effects of ACE inhibition on coronary artery disease
22. Angiotensin II and connective tissue: Homeostasis and reciprocal regulation
23. Extra-adrenal mineralocorticoids and cardiovascular tissue
24. Production of aldosterone in isolated rat blood vessels
25. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin
26. Myocardial production of aldosterone and corticosterone in the rat: Physiological regulation
27. Activation of cardiac aldosterone production in rat myocardial infarction: Effect of angiotensin II receptor blockade and role in cardiac fibrosis
28. Studies on congestive heart failure. II. Impaired renal excretion of sodium chloride
29. Cardiac output, blood and interstitial fluid volumes, total circulating serum protein, and kidney function during cardiac failure and after improvement
30. Edema and decreased renal blood flow in patients with chronic congestive heart failure: Evidence of "forward failure" as the primary cause of edema
31. Fluid dynamics in chronic congestive heart failure: An interpretation of the mechanisms producing the edema, increased plasma volume and elevated venous pressure in certain patients with prolonged congestive failure
32. The role of the cardiac output in the mechanisms of congestive heart failure
33. The correspondence of S A.S. Simpson and J.F. Tait with T. Reichstein during their collaborative work on the isolation and elucidation of the structure of electrocortin (later aldosterone)
34. Hormones and the pathogenesis of congestive heart failure: Vasopressin, aldosterone, and angiotensin II. Further evidence for renal-adrenal interaction from studies in hypertension and in cirrhosis
35. Sodium-dependent modulation of the renal Na-K-ATPase: Influence of mineralocorticoids on the cortical collecting duct
36. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia
37. Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction
38. Action of new steroids in blocking effects of aldosterone and deoxycorticosterone on salt
39. Aldosterone antagonists
40. Mode of action and clinical usefulness of aldosterone antagonists
41. Response of normal subjects to large amounts of aldosterone
42. Nature of renal escape from the sodium-retaining effect of aldosterone in primary aldosteronism and in normal subjects
43. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease
44. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
45. Neural regulation of sympathetic nerve activity in heart failure
46. Compensatory renal growth after unilateral nephrectomy in the new-born rat
47. The fine structure of compensatory growth in the rat kidney after unilateral nephrectomy
48. Morphological and physiological responses to aldosterone: Time course and sodium dependence
49. Structural and functional study of the rat distal nephron: Effects of potassium adaptation and depletion
50. Distal tubular segments of the rabbit kidney after adaptation to altered Na- and K-intake. I. Structural changes
51. Regulation of the sodium pump: How and why?
52. Aldosterone regulation of gene transcription leading to control of ion transport
53. The general adaptation syndrome and the diseases of adaptation
54. Hypertension and hypersalimentation. I. Aldosterone hypertension
55. Myocardial fibrosis: Functional significance and regulatory factors
56. Chaos in the hall of mirrors
57. Squeezing tubes: A case of remodeling and regulation. Coronary reserve in hypertensive heart disease
58. Remodeling of the rat right and left ventricle in experimental hypertension
59. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism
60. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion
61. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats
62. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone
63. Fibrosis of the human heart and systemic organs in adrenal adenoma
64. Increased cardiac types I and III collagen mRNAs in aldosteronesalt hypertension
65. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states
66. Mineralocorticoids, hypertension, and cardiac fibrosis
67. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
68. Role of aldosterone in the remnant kidney model in the rat
69. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation
70. +ATPase: Mechanisms underlying rapid and sustained changes in pump activity
71. +-ATPase α-subunit gene expression in hypertension
72. Sodium and water balance in chronic congestive heart failure
73. Regulation of glomerular filtration rate in chronic congestive heart failure patients
74. Aldosterone and antialdosterone therapy in congestive heart failure
75. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES)
76. Increased serum concentrations of procollagen peptides in essential hypertension: Relation to cardiac alterations
77. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: Relation to myocardial fibrosis
78. Abnormalities of the extracellular degradation of collagen type I in essential hypertension
79. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease
80. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis
81. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients
82. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival study (CONSENSUS)
83. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
84. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
85. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: Baseline predictors and impact of long-term use of captopril. Information from the Survival and Ventricular Enlargement (SAVE) trial
86. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure